Xocova FDA Nod: COVID Post-Exposure Prevention

Key Takeaways

• FDA approved Xocova (ensitrelvir) for post-exposure prophylaxis of COVID-19 in people 12 years and older following contact with an infected individual, per Shionogi’s June 1, 2026 announcement mirrored in wire coverage.
• The labeled U.S. use is prevention after exposure, not treatment of active COVID-19 infection.
• SCORPIO-PEP dosed 375 mg on day 1 and 125 mg on days 2–5, starting within 72 hours of the index patient’s symptom onset.
• Company-reported SCORPIO-PEP results describe a 67% reduction in symptomatic COVID-19 risk versus placebo through day 10 among participants negative at baseline.

What did FDA authorize for Xocova in June 2026?

According to Shionogi’s June 1, 2026 disclosure as carried on company and secondary medical outlets, FDA approved oral ensitrelvir (XOCOVA) for post-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older after contact with someone who has COVID-19. Approval arrived ahead of the stated PDUFA action date of June 16, 2026.

The U.S. indication is prophylaxis, not treatment. Japan already had treatment and prevention pathways historically; U.S. labeling should be read separately.

For clinical context on COVID antivirals and prevention, see CDC COVID-19 hub.

What regimen and timing does SCORPIO-PEP support?

Company materials describe a five-day oral course: 375 mg (three tablets) on day 1, then 125 mg daily on days 2 through 5. Participants in SCORPIO-PEP began treatment within 72 hours of when the household index patient began showing symptoms and were randomized 1:1 to ensitrelvir or placebo.

Registry lookup for related ensitrelvir COVID studies should start at ClinicalTrials.gov using ensitrelvir or SCORPIO keywords before advisory-board slides are finalized.

How strong was the prevention endpoint?

Shionogi reported that SCORPIO-PEP met its primary endpoint for preventing symptomatic COVID-19 after exposure. Company figures describe a 67% relative reduction in symptomatic disease through day 10 versus placebo among participants who were not infected at baseline (example reported rates: 2.9% versus 9.0% in detailed secondary writeups of the same disclosure).

Until FDA publishes the full label on Drugs@FDA / DailyMed, medical teams should quote company primary disclosures carefully and update when the official U.S. prescribing information posts.

Watch FDA Drugs and DailyMed for the formal label.

What is explicitly not approved in the United States?

Company corrections language states XOCOVA is not approved for treatment of COVID-19 in the U.S., even though Japan granted treatment approvals earlier based on SCORPIO-SR work published in JAMA Network Open.

JAMA Network Open publication trail for Asian treatment data: JAMA Network. Do not blend Japan treatment claims into U.S. PEP promotion.

What should APAC commercial and medical teams prepare next?

APAC teams already familiar with Japan’s Xocova franchise need U.S.-specific objection handlers: PEP-only indication, five-day load/maintenance dosing, 72-hour start window, and vaccination-status subgroup language only if present in the U.S. label.

• Rebuild HCP FAQs around exposure timing, not symptomatic treatment
• Align pharmacovigilance intake for dysgeusia and other adverse events reported in trials
• Track CDC clinical considerations for COVID prevention products as they update

CDC clinical landing pages remain the public-health counterpart to the FDA approval: CDC COVID clinical care.

What remains unproven?

Do not invent effectiveness against future variants, pediatric use under age 12, or treatment benefit in U.S. outpatients. Those claims are outside the June 2026 U.S. PEP approval narrative sourced here.

Related NovaPharma coverage

• Childhood vaccine schedule policy shift
• Direct-to-patient pharma access
• Merck Phase 3 pipeline

Frequently Asked Questions

Primary Sources

1. FDA — Drugs
2. ClinicalTrials.gov
3. CDC — COVID-19
4. JAMA Network